VNRX
Volitionrx LtdSubstantial doubt about the company's ability to continue as a going concern.
“The possibility that we may not be able to continue to operate, as indicated by the “going concern” opinion from our auditors”View the 10-Q filed May 14, 2026
Price & Indicators
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VNRX
this stock
Volitionrx Ltd
|
$9.66M | -77.7% | +40.0% | — | 3.9% |
|
ABT
Abbott Laboratories
|
$172.14B | -20.7% | +5.7% | 27.7 | 1.3% |
|
SYK
Stryker Corp
|
$126.97B | -5.5% | +11.2% | 38.3 | 1.8% |
|
MDT
Medtronic plc
|
$106.96B | -12.3% | +8.4% | 22.4 | 1.5% |
|
BSX
Boston Scientific Corp
|
$66.32B | -53.2% | +5.5% | 18.7 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VNRX | -13.4% | -17.1% | -80.0% | -14.1% | -77.7% |
| SPY | -0.1% | +0.1% | +9.0% | +0.5% | +10.1% |
| vs SPY | -13.3% | -17.2% | -89.0% | -14.6% | -87.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.